The global blood
cell analyzer market is estimated to rise from US$1,364.2 Mn in 2017
to reach a worth of US$1,844.9 Mn by end of 2022. The market is
anticipated to clock a CAGR of 6.2% from 2017 to 2022.
Blood cell analyzers
are commercially used in laboratory settings for characterizing
various components of blood, notably complete blood count and
differential counts, for the detection of various blood-related
disorders and several common physiological indications. The wide
application of blood analysis for diagnosing indications such as
anemia, diabetes, autoimmune disorders, and cancer is boosting the
evolution of the market. The rapid evolution of automated cell
counters that incorporates a large number of analysis parameters into
a single instrument platform with the ability to offer rapid results
is a notable development catalyzing the growth of the market. In
recent years, the market has witnessed the advent of diagnostic
point-of-care analyzers that offer reliable precise results, thereby
facilitating faster treatment. Advancement in chemical reagents and
physical technologies used in blood cell analyzers bodes well for the
market.
The growing demand
for hematology analyzers for the detection of several common
blood-related disorders in various clinical settings is a key factor
driving the market. The growing use of blood cell analyzers in
diagnosing blood transfusion-transmitted infections world over is a
key factor accentuating the market. The rise in number of blood
donations in a number of developing and developed countries is a
prominent trend bolstering the demand for blood cell analyzers in
these regions. In addition, the vastly emerging application of blood
cell analyzers in the assessment of cardiovascular diseases and in
the classification of bone marrow disorders are key trends boosting
the market.
Request for
Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33728
However, the high
cost of automated instruments has hampered their adoption in several
less developed nations. Nevertheless, the demand for high-quality
solutions for improving the laboratory workflow and enhancing
customer patient care is expected to stimulate advancement in
automated blood cell analyzers. The innovative use of reagents and
substantial advances in flow cytometry by manufacturers bodes well
for the market. Furthermore, the search for novel plasma-based
therapeutics is expected to unlock exciting opportunities for market
players in the coming years.
The intensifying
need for high-performing, automated analyzers that can provide
high-throughput analysis with reduces turnaround time is a notable
aspect expected to open up exciting avenues for market players in
various regions. Recent advancements in automated cell counters and
sensor technology has considerably minimized the error in the
functioning of blood cell analyzers.
Request a
Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33728
Geographically,
North America holds the major share, vis-à-vis revenue, of the
global market and is expected to account to lead throughout the
assessment period. The opportunities in the regional market is
projected to reach US$717.5 Mn by 2022 end. The dominance of the
regional market is attributed mainly to the vastly rising demand for
advanced semi- and fully-automated blood cell analyzers in various
clinical settings. Of all the product type, fully automated
biochemistry analyzers is the leading segment and is anticipated to
retain its dominance for the next few years as well. The segment is
projected to hold a whopping share of 80.0% by the end of 2022.
Several emerging and
leading players are launching comprehensive and advanced solutions
with new applications for different clinical settings, with a move to
consolidate their shares in various regions. Some of the leading
players operating in the market are Sysmex Corporation, Abbott
Laboratories, Danaher Corporation, Siemens Healthcare, Horiba Ltd,
Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Sigma Aldrich,
and Boule Diagnostics AB.
Enquiry for
discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33728
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment